Zenas BioPharma (ZBIO) Competitors $19.90 +0.94 (+4.96%) As of 11:03 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZBIO vs. LGND, FOLD, MNKD, CLDX, BCRX, NVAX, INVA, DVAX, OPK, and GERNShould you be buying Zenas BioPharma stock or one of its competitors? The main competitors of Zenas BioPharma include Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), MannKind (MNKD), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), Dynavax Technologies (DVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry. Zenas BioPharma vs. Its Competitors Ligand Pharmaceuticals Amicus Therapeutics MannKind Celldex Therapeutics BioCryst Pharmaceuticals Novavax Innoviva Dynavax Technologies OPKO Health Geron Ligand Pharmaceuticals (NASDAQ:LGND) and Zenas BioPharma (NASDAQ:ZBIO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership. Which has better earnings and valuation, LGND or ZBIO? Ligand Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$187.58M17.91-$4.03M-$4.00-42.86Zenas BioPharma$5M167.43-$156.99M-$3.55-5.60 Do institutionals & insiders believe in LGND or ZBIO? 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 16.5% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is LGND or ZBIO more profitable? Zenas BioPharma has a net margin of 0.00% compared to Ligand Pharmaceuticals' net margin of -40.44%. Ligand Pharmaceuticals' return on equity of -9.21% beat Zenas BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals-40.44% -9.21% -8.09% Zenas BioPharma N/A -59.21%-50.56% Does the media favor LGND or ZBIO? In the previous week, Ligand Pharmaceuticals had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 5 mentions for Ligand Pharmaceuticals and 1 mentions for Zenas BioPharma. Ligand Pharmaceuticals' average media sentiment score of 0.88 beat Zenas BioPharma's score of 0.67 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend LGND or ZBIO? Ligand Pharmaceuticals presently has a consensus target price of $176.50, indicating a potential upside of 2.95%. Zenas BioPharma has a consensus target price of $36.67, indicating a potential upside of 84.44%. Given Zenas BioPharma's higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Zenas BioPharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryLigand Pharmaceuticals beats Zenas BioPharma on 8 of the 14 factors compared between the two stocks. Get Zenas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ZBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZBIO vs. The Competition Export to ExcelMetricZenas BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$837.15M$3.13B$5.72B$10.40BDividend YieldN/A2.36%5.53%4.58%P/E Ratio-5.6021.0076.4326.62Price / Sales167.43255.87472.7192.34Price / CashN/A46.3537.4661.85Price / Book2.669.8013.276.45Net Income-$156.99M-$52.73M$3.29B$271.39M7 Day Performance4.25%4.70%2.60%3.06%1 Month Performance16.26%6.23%4.65%7.62%1 Year PerformanceN/A18.77%74.34%30.20% Zenas BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZBIOZenas BioPharma1.1125 of 5 stars$19.90+5.0%$36.67+84.3%N/A$837.99M$5M-5.61N/AGap UpLGNDLigand Pharmaceuticals4.0191 of 5 stars$166.24+0.4%$176.50+6.2%+71.2%$3.24B$167.13M-41.5680High Trading VolumeFOLDAmicus Therapeutics3.9363 of 5 stars$8.01+3.6%$16.00+99.8%-27.3%$2.38B$528.29M-66.74480High Trading VolumeMNKDMannKind4.297 of 5 stars$5.37-0.2%$11.17+107.9%-17.9%$1.65B$285.50M48.82400Positive NewsCLDXCelldex Therapeutics1.8 of 5 stars$24.58+0.3%$46.67+89.9%-39.7%$1.63B$7.02M-8.17150BCRXBioCryst Pharmaceuticals4.2741 of 5 stars$7.75+0.6%$16.70+115.5%+0.4%$1.62B$450.71M-43.05530Positive NewsNVAXNovavax4.2316 of 5 stars$8.56+5.9%$14.29+66.9%-32.3%$1.31B$682.16M3.751,990INVAInnoviva4.7834 of 5 stars$19.34-1.1%$42.75+121.0%+1.0%$1.23B$358.71M62.39100Analyst UpgradeDVAXDynavax Technologies4.1913 of 5 stars$9.70+3.6%$24.33+150.9%-13.7%$1.10B$277.25M-21.09350OPKOPKO Health4.4708 of 5 stars$1.39+0.7%$2.75+97.8%-4.0%$1.10B$713.10M-5.562,997News CoverageGERNGeron2.6227 of 5 stars$1.25-1.6%$3.79+202.9%-68.7%$810.28M$76.99M-9.6270Positive NewsHigh Trading Volume Related Companies and Tools Related Companies LGND Alternatives FOLD Alternatives MNKD Alternatives CLDX Alternatives BCRX Alternatives NVAX Alternatives INVA Alternatives DVAX Alternatives OPK Alternatives GERN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZBIO) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZBIO Stock Alerts